Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
School of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Bone Marrow Transplant. 2023 Sep;58(9):973-979. doi: 10.1038/s41409-023-02038-9. Epub 2023 Aug 3.
Acute gastrointestinal graft versus host disease (GI-GVHD) is a common complication following allogeneic haematopoietic cell transplantation (HCT), and is characterised by severe morbidity, frequent treatment-refractoriness, and high mortality. Early, accurate identification of GI-GVHD could allow for therapeutic interventions to ameliorate its severity, improve response rates and survival; however, standard endoscopic biopsy is inadequately informative in terms of diagnostic sensitivity or outcome prediction. In an era where rapid technological and laboratory advances have dramatically expanded our understanding of GI-GVHD biology and potential therapeutic targets, there is substantial scope for novel investigations that can precisely guide GI-GVHD management. In particular, the combination of tissue-based biomarker assessment (plasma cytokines, faecal microbiome) and molecular imaging by positron emission tomography (PET) offers the potential for non-invasive, real-time in vivo assessment of donor:recipient immune activity within the GI tract for GI-GVHD prediction or diagnosis. In this article, we review the evidence regarding GI-GVHD diagnosis, and examine the potential roles and translational opportunities posed by these novel diagnostic tools, with a focus on the evolving role of PET.
急性胃肠道移植物抗宿主病(GI-GVHD)是异基因造血细胞移植(HCT)后的常见并发症,其特征为严重发病率、频繁治疗抵抗和高死亡率。早期、准确识别 GI-GVHD 可进行治疗干预以改善其严重程度、提高反应率和生存率;然而,标准内镜活检在诊断敏感性或预后预测方面的信息不足。在一个快速的技术和实验室进步极大地扩展了我们对 GI-GVHD 生物学和潜在治疗靶点的理解的时代,有很大的空间进行可以精确指导 GI-GVHD 管理的新研究。特别是,组织生物标志物评估(血浆细胞因子、粪便微生物组)与正电子发射断层扫描(PET)的分子成像相结合,为 GI-GVHD 预测或诊断提供了在胃肠道内非侵入性、实时体内评估供体:受者免疫活性的潜力。在本文中,我们回顾了关于 GI-GVHD 诊断的证据,并研究了这些新型诊断工具所带来的潜在作用和转化机会,重点是 PET 的不断发展作用。